Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback